Literature DB >> 25794498

Role of sodium fluoride PET imaging for identification of bony metastases in prostate cancer patients.

C Tanner Hughes1, Jeffrey Wells Nix.   

Abstract

Sodium fluoride (Na-F) PET/CT is an imaging technique which allows radiolabeled fluoride to help detect areas of bone turnover. Detecting metastatic prostate cancer earlier than is currently possible with standard imaging may help prevent unnecessary morbidity for patients and improve staging in an effort to more accurately select the appropriate therapy at an appropriate time. Na-F PET/CT has been investigated as a means to help detect osseous metastatic disease in prostate cancer. It is still unclear which clinical circumstances are beneficial for a patient to undergo Na-F PET/CT in addition to, or instead of, the current standard imaging. This review examines the most recent publications related to this topic.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25794498     DOI： 10.1007/s11934-015-0500-3

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  14 in total

1.  Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy.

Authors:  Frank I Lin; Jyotsna E Rao; Erik S Mittra; Kavitha Nallapareddy; Alka Chengapa; David W Dick; Sanjiv Sam Gambhir; Andrei Iagaru
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-08       Impact factor: 9.236

2.  Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases.

Authors:  Urban Simoncic; Scott Perlman; Glenn Liu; Mary Jane Staab; Jane Elizabeth Straus; Robert Jeraj
Journal:  Clin Genitourin Cancer       Date:  2014-07-15       Impact factor: 2.872

3.  Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.

Authors:  Mads H Poulsen; Henrik Petersen; Poul F Høilund-Carlsen; Jørn S Jakobsen; Oke Gerke; Jens Karstoft; Signe I Steffansen; Steen Walter
Journal:  BJU Int       Date:  2014-05-22       Impact factor: 5.588

4.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.

Authors:  Einat Even-Sapir; Ur Metser; Eyal Mishani; Gennady Lievshitz; Hedva Lerman; Ilan Leibovitch
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

5.  Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.

Authors:  F M Chybowski; J J Keller; E J Bergstralh; J E Oesterling
Journal:  J Urol       Date:  1991-02       Impact factor: 7.450

6.  Prostate cancer, version 2.2014.

Authors:  James L Mohler; Philip W Kantoff; Andrew J Armstrong; Robert R Bahnson; Michael Cohen; Anthony Victor D'Amico; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric Mark Horwitz; Christopher J Kane; Mark H Kawachi; Michael Kuettel; Timothy M Kuzel; Richard J Lee; Arnold W Malcolm; David Miller; Elizabeth R Plimack; Julio M Pow-Sang; David Raben; Sylvia Richey; Mack Roach; Eric Rohren; Stan Rosenfeld; Edward Schaeffer; Eric J Small; Guru Sonpavde; Sandy Srinivas; Cy Stein; Seth A Strope; Jonathan Tward; Dorothy A Shead; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2014-05       Impact factor: 11.908

7.  Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry.

Authors:  Bruce E Hillner; Barry A Siegel; Lucy Hanna; Fenghai Duan; Anthony F Shields; R Edward Coleman
Journal:  J Nucl Med       Date:  2014-02-27       Impact factor: 10.057

8.  Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.

Authors:  Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Wolfgang Loidl; Gabriele Broinger; Franz Stoiber; Ignac Foglman; Werner Langsteger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

Review 9.  Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice.

Authors:  Sarah Bastawrous; Puneet Bhargava; Fatemeh Behnia; David S W Djang; David R Haseley
Journal:  Radiographics       Date:  2014 Sep-Oct       Impact factor: 5.333

10.  FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

Authors:  Ronald Boellaard; Mike J O'Doherty; Wolfgang A Weber; Felix M Mottaghy; Markus N Lonsdale; Sigrid G Stroobants; Wim J G Oyen; Joerg Kotzerke; Otto S Hoekstra; Jan Pruim; Paul K Marsden; Klaus Tatsch; Corneline J Hoekstra; Eric P Visser; Bertjan Arends; Fred J Verzijlbergen; Josee M Zijlstra; Emile F I Comans; Adriaan A Lammertsma; Anne M Paans; Antoon T Willemsen; Thomas Beyer; Andreas Bockisch; Cornelia Schaefer-Prokop; Dominique Delbeke; Richard P Baum; Arturo Chiti; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236
View more
  2 in total

Review 1.  PET imaging of recurrent and metastatic prostate cancer with novel tracers.

Authors:  Francesca V Mertan; Liza Lindenberg; Peter L Choyke; Baris Turkbey
Journal:  Future Oncol       Date:  2016-08-16       Impact factor: 3.404

2.  Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting 18F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical Prostatectomy.

Authors:  James Yoon; Leslie Ballas; Bhushan Desai; Hossein Jadvar
Journal:  World J Nucl Med       Date:  2017 Jul-Sep
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.